Sign in

SQNM on NYSE

Sequenom

Logo: sequenom.com4

American life sciences company

Sequenom, Inc. is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT. Sequenom's wholly owned subsidiary, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, and the SensiGene RHD Fetal RHD genotyping test.3 Its shares trade on NYSE under the symbol SQNM.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 1994Founded1

Compare with another stock.

  • TickerSQNM on NYSE1
  • Industrybiotechnology1
  • HeadquartersSan Diego1
  • Websitewww.sequenom.com
  • Legal formcorporation1
  • Incorporated inDE5
  • Business address3595 John Hopkins Court, San Diego, X1 921215
  • Filer categoryAccelerated filer5

See how the biggest companies compare on our leaderboards

Sequenom, Inc. is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT. Sequenom's wholly owned subsidiary, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, and the SensiGene RHD Fetal RHD genotyping test.3

Corporate structure

Sequenom sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Sequenom San Diego
    • Sequenom (United Kingdom) Subsidiary · United Kingdom

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sequenom reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$65.3M7 Dec 31, 2015$65.8M7 Dec 31, 2014−0.7%
Accumulated depreciation$55.3M7 Dec 31, 2015$50.4M7 Dec 31, 2014+9.6%
Property and equipment, net$10.1M7 Dec 31, 2015$15.3M7 Dec 31, 2014−34.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$50.3M7 Dec 31, 2015$63.3M7 Dec 31, 2014−20.5%
Marketable securities, current$25.8M7 Dec 31, 2015$30.6M7 Dec 31, 2014−15.6%
Debt securities held to maturity$25.6M7 Dec 31, 2015$30.4M7 Dec 31, 2014−15.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$10.0M7 Dec 31, 2015$10.0M7 Dec 31, 20140%
Intangible assets, net (excluding goodwill)$8.1M7 Dec 31, 2015$11.2M7 Dec 31, 2014−28.1%
Finite-lived intangibles, gross$13.9M8 Dec 31, 2014
Accumulated amortization$2.7M8 Dec 31, 2014
Finite-lived intangibles, net$8.1M7 Dec 31, 2015$11.2M8 Dec 31, 2014−28.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.4M7 Dec 31, 2015$6.5M7 Dec 31, 2014−62.9%
Raw materials$2.1M7 Dec 31, 2015$6.2M7 Dec 31, 2014−65.2%
Work in process$272.0K7 Dec 31, 2015$351.0K7 Dec 31, 2014−22.5%

The story

On August 4, 2011, Sequenom said it would call its new blood test for Down syndrome in pregnancy MaterniT21 when the product went on sale in the United States.

On August 11, 2011, Sequenom announced a European licensing agreement with LifeCodexx. The companies agreed to collaborate in the development and launch of a trisomy 21 laboratory-developed test and other aneuploidies testing in Germany, Austria, Switzerland, and Liechtenstein, with the potential for additional launches in other countries. Under the initial five year licensing agreement, Sequenom granted LifeCodexx licenses to key patent rights, including European Patent EP0994963B1 and pending application EP2183693A1 that enable the development and commercialization of a non-invasive aneuploidy test utilizing circulating cell-free fetal DNA in maternal plasma.

On October 24, 2011 International Society of Prenatal Diagnostics (ISPD) issued a rapid response statement in response to the launch of Sequenom non-invasive Trisomy 21 (MaterniT21) test.

On October 17, 2011 Sequenom announced that a clinical validation study leading to the introduction of the MaterniT21 LDT had been published in the journal Genetics in Medicine. On October 17, 2011 Sequenom Center for Molecular Medicine announced the launch of MaterniT21 Noninvasive Prenatal Test for Down Syndrome.

From Wikipedia’s article on Sequenom, shared under CC BY-SA 4.0.6

Leadership

Who has led Sequenom, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Harry Stylli2006–2009
  2. Harry F. Hixson Jr.2009–2014
  3. William J. Welch2014–2015

Chair

  1. F. Samuel Eberts Iii.2016

President

  1. Harry Stylli2006–2009
  2. William J. Welch2012–2015
  3. F. Samuel Eberts Iii.2016

Chief financial officer

  1. Paul W. Hawran2007–2009
  2. Paul Maier V.2009–2014
  3. Carolyn Beaver2014–2016

Chief operating officer

  1. William J. Welch2012–2014
1995200020052010201520202025
Board members and other officers (45)

Subsidiaries and ownership

Owners

Subsidiaries

  • Sequenom (United Kingdom)

From Wikidata.1

Timeline

  1. Jun 11, 2014New chief executive William J. Welch becomes CEO9
  2. Oct 23, 2009New chief executive Harry F. Hixson Jr. becomes CEO10
  3. Jun 8, 2006New chief executive Harry Stylli becomes CEO11
  4. Jan 1, 1994Founded Founded1

SEC filer profile

How Sequenom is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSEQUENOM INC2
  • CIK0001076481
  • Employer ID (EIN)77-03658892
  • Filer statusAccelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)3829 Measuring & Controlling Devices, NEC2
  • Business address3595 John Hopkins Court, San Diego, X1 921212
  • Phone85820290002
  • Shares outstanding119,243,357 as of Jul 25, 201659
  • Public float$357.1M as of Jun 30, 20157
  • On EDGAR sinceNov 24, 19992
  • Filings1,203 in all: 4 (485), 8-K (209), SC 13G/A (57), 3 (52), 10-Q (50), SC 13G (32), DEFA14A (23), 4/A (21)2
    All 57 form types

    CT ORDER (18), 10-K (16), DEF 14A (16), CORRESP (15), S-8 (15), SC 13D/A (15), UPLOAD (15), S-8 POS (13), ARS (12), EFFECT (11), 424B3 (10), 10-K/A (9), S-3 (8), 424B5 (7), 425 (7), SC 13D (7), SC 14D9/A (7), 8-K/A (6), REGDEX (6), S-1/A (6), SC TO-T/A (6), S-3/A (5), D (4), POS AM (4), PRE 14A (4), 10-Q/A (3), 3/A (2), 424B4 (2), SC TO-I/A (2), SC TO-T (2), SC14D9C (2), SD (2), 10-K405 (1), 15-12G (1), 25-NSE (1), 5 (1), 8-A12G (1), 8-A12G/A (1), DEFM14A (1), NT 10-K (1), PREM14A (1), RW (1), S-1 (1), S-1MEF (1), S-3ASR (1), S-4 (1), SC 14D9 (1), SC TO-C (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2016
    Quarterly report (10-Q) Aug 5, 2016
    Proxy statement (DEF 14A) Apr 27, 2016
    Latest 8-K (8-K) Sep 7, 2016

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Company websiteSequenom logo
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59